New Pathways to Control Moderate to Severe Asthma
PROGRAM DESCRIPTION Welcome to the inaugural myCME TOWN WALL™. This unique platform allows you to hear from a wide variety of experts through an engaging visual display. The focus of ...
Welcome to the inaugural myCME TOWN WALL™. This unique platform allows you to hear from a wide variety of experts through an engaging visual display. The focus of this program is severe asthma.Given the chronic and inflammatory nature of asthma, many patients with asthma have persistent daily symptoms and exacerbations despite compliance with high doses of inhaled steroids, long-acting beta-agonists, and other supplemental therapies. Factors that play a role in poor asthma control include clinician lack of awareness of current treatment guidelines and a failure to use validated tools to assess severity; different perceptions or definitions of control between the patient and the clinician; lack of adherence to therapy; poor inhaler technique and inadequate dosing; and patient misconceptions regarding specific agents. In light of these challenges, respiratory specialists and primary care providers should become familiar with inflammatory mediators such as immunoglobulin E (IgE), interleukin-5 (IL-5), and IL-13, along with recently approved asthma therapies that address the pathophysiologic abnormalities associated with moderate to severe, often hard-to-treat asthma. For such patients, there is a need to integrate into practice contemporary approaches to asthma management that are aligned with published guidelines and accepted standards of care. Healthcare providers also should work in concert with patients in the selection of therapies and of the most appropriate delivery device to foster improved adherence and overall outcomes.
After completing the activity, the participant should be better able to:Evaluate the role of inflammatory mediators and other abnormalities in the pathogenesis of asthmaApply evidence-based guidelines to individualized treatment plans for patients with asthmaDevelop collaborative treatment strategies and a stronger provider-patient partnership to ensure optimal control of moderate to severe asthmaAnalyze the safety and efficacy of new and emerging agents for the management of poorly controlled asthma
I'm interested in this
Share with others
Write the first review
Share with others